Лучшие подкасты про Talking Oncology (2024)

1
01_14 Ampullary Carcinoma (Mini Discussion) 10:59

8d ago10:59

10:59

1. Clinical presentation and work-up 2. Intestinal and pancreatobiliary subtypes 3. Role of perioperative therapy 4. Considerations for metastatic disease Citations As always, citations, and sources include education from our respective training programs, the Devita textbook, and Uptodate.com. We highly encourage review of guidelines published by A…

1
Artificial Intelligence Tool Predicts Postoperative Radiotherapy Lymphedema 34:36

3d ago34:36

34:36

Artificial intelligence is being harnessed by a team of researchers at Leicester University in the United Kingdom to predict the risk of lymphedema (and potentially other toxicities) from the use of postoperative radiation therapy for breast cancer. The 2024 European Breast Cancer Conference heard the latest news on an artificial intelligence tool …

1
Neoadjuvant Pembrolizumab Improves High-Risk Early Breast Cancer Outcomes 8:47

3d ago8:47

8:47

New data from the Phase III KEYNOTE-756 clinical trial show that adding pembrolizumab immunotherapy to chemotherapy before and after surgery for high-risk breast cancer (which was estrogen receptor (ER)-positive and human epidermal growth factor receptor 2 (HER2)-negative) resulted in better outcomes for patients regardless of their age or menopaus…

1
Preoperative Partial Breast Irradiation: Marked Benefit in Low-Risk Breast Cancer 9:00

6d ago9:00

9:00

Offering MRI-guided partial breast irradiation before surgery to patients with low-risk breast cancer could become the norm, according to Yasmin Civil, MD, in the Department of Radiation Oncology at the Amsterdam UMC in the Netherlands, who reported 5-year results from the ABLATIVE trial to the 14th European Breast Cancer Conference. The researcher…

1
Adjuvant Atezolizumab: No Survival Benefit in Triple-Negative Breast Cancer 9:35

7d ago9:35

9:35

Adding checkpoint inhibition immunotherapy to adjuvant chemotherapy did not improve survival among patients with triple-negative breast cancers. These findings from a study reported at the 14th European Breast Cancer Conference were presented by Heather McArthur, MD, MPH, Clinical Director of Breast Cancer and Komen Distinguished Chair in Clinical …

1
Gene Test Shows Which Triple-Negative Breast Cancers Do Not Need Pre-Op Pembrolizumab 15:44

22d ago15:44

15:44

About a quarter of all patients with newly diagnosed triple-negative breast cancer will not benefit from neoadjuvant checkpoint inhibitor immunotherapy with an agent such as pembrolizumab—even though it improves outcomes among the remaining majority. At the 14th European Breast Cancer Conference, held in Milan, Italy, Laura van ’t Veer, PhD, Progra…

1
Triple Therapy for Patients With Mutated FLT3 Gene in Acute Myeloid Leukemia 20:15

28d ago20:15

20:15

An early study of patients (Phase I/II) with acute myeloid leukemia found that a new three-drug combination therapy greatly improved outcomes—both in patients with relapsed or refractory disease and as initial therapy. The new research involved adding quizartinib that targets fms-related tyrosine kinase 3 (FLT3) oncogene. Mutations of FLT3 are pres…

1
Important Mantle Cell Lymphoma Findings From the Sympatico Study 13:55

1M ago13:55

13:55

How best to treat patients with relapsed or refractory mantle cell lymphoma has been made clearer by a report from the multinational Phase III Sympatico Study, presented at the 65th ASH Annual Meeting and Exposition held in San Diego. Lead author Michael Wang, MD, Professor in the Department of Lymphoma & Myeloma at the University of Texas MD Ander…

1
World’s Largest Prostate Cancer Trial, STAMPEDE, Celebrates 20 Years of Progress 17:44

1M ago17:44

17:44

2024 is the 20th year of clinical studies conducted as part of the STAMPEDE (Systemic Therapy in Advancing or Metastatic Prostate Cancer: Evaluation of Drug Efficacy) trial, a series of investigational approaches to initial therapy for patients with high-risk prostate cancer. Patient accrual has now ended, but practice-changing data continue to eme…

1
Doublet Inhibitor Therapy Restrains Metastatic EGFR-Mutated NSCLC Progression 16:00

2M ago16:00

16:00

The multicenter RAMOSE randomized clinical trial has found that doublet growth factor tyrosine kinase inhibitor therapy, when compared with standard osimertinib monotherapy, achieved a statistically significant improvement in progression-free survival in patients whose advanced non-small cell lung cancers were driven by mutated epidermal growth fac…

1
Gene-Targeted Agent Brings Clinical Benefit in R/R Acute Leukemias 24:23

2M ago24:23

24:23

A new targeted drug, revumenib, was found to increase response rates and survival in patients whose previously treated acute leukemias relapsed or were refractory to treatment. A Phase II clinical study found revumenib met its primary endpoint and was stopped early because of a high patient response rate and clinical efficacy. Revumenib acts on the…

1
INTERLACE Study Boosts Cervical Cancer Survival 18:14

2M ago18:14

18:14

A marked improvement in the outlook for patients with locally advanced cervical cancer has been achieved thanks to a neoadjuvant regimen using standard anti-cancer drugs added to usual therapy. At the ESMO Congress 2023 held in Madrid, Spain, Mary McCormack, PhD, MBBS, FRCR, Consultant Clinical Oncologist at University College London Hospitals, rep…

1
04_04 Castrate Resistant Metastatic Prostate Cancer 24:50

2M ago24:50

24:50

1. On continuation of ADT and ARAT switch 2. Systemic therapy options after progression 3. Improper mandated crossover 4. PARP inhibitors in prostate cancer Citations As always, citations, and sources include education from our respective training programs, the Devita textbook, and Uptodate.com. We highly encourage review of guidelines published by…

1
RET Fusion-Targeted Drug Doubles Progression-Free Survival in NSCLC Patients 18:43

2M ago18:43

18:43

Patients whose advanced non-small cell lung cancers harbor the RET gene fusion should receive initial treatment with the RET-targeted agent selpercatinib rather than chemotherapy or chemotherapy combined with immunotherapy. This clear message comes from the randomized Phase III LIBRETTO-431 study reported at ESMO Congress 2023 by Herbert Ho Fung Lo…

1
Afatinib Recommended for Non-Small Cell Lung Cancer With Uncommon EGFR Mutations 8:33

2M ago8:33

8:33

The preferred first-line treatment for patients with uncommon sensitizing mutations in tumor epidermal growth factor receptor (EGFR) should now be the tyrosine kinase inhibitor (TKI) afatinib, rather than osimertinib, according to Japanese researchers reporting the ACHILLES trial results at the ESMO Congress 2023 held in Madrid. OncTimesTalk corres…

1
Adjuvant Radiotherapy No Benefit After Radical Prostatectomy 15:24

2M ago15:24

15:24

Patients with high-risk prostate cancer who have been treated with radical prostatectomy gain no additional advantage and face extra toxicity if they choose to have adjuvant radiotherapy. That’s according to the findings of the randomized RADICALS study, reported at the ESMO Congress 2023. These results support the use of early salvage radiotherapy…

1
Collagen-Bound Interleukin 12 Converts “Cold” Tumors Into “Hot” Ones 14:51

2M ago14:51

14:51

Although immunotherapies for patients with solid tumors such as melanoma can be dramatically successful, the majority of patients are resistant and require alternative treatments. While the cytokine interleukin-12 is well known for potentiating the effect of immunotherapies, such as checkpoint blockade, it couldn’t be used because of toxicity. At t…

1
Best Gems & Highlights of 2023: Part 1 25:24

2M ago25:24

25:24

This is Part One of a two-part series where we revisit the most inspiring stories and insights from our episodes in 2023. From courageous journeys to triumphant victories, we honor the resilience and wisdom of real cancer patients and survivors. Amidst these powerful narratives, we also pay tribute to those who have left an indelible mark on our he…

1
Allogeneic Transplant for AML: Only in Patients Negative for Molecular Minimum Residual Disease 15:43

2M ago15:43

15:43

The process of identifying which patients with acute myeloid leukemia (AML) can benefit from allogeneic stem cell transplantation in first complete remission (CR1) has taken a step forward thanks to analysis of the UK NCRI AML17 and AML19 studies, reported at the 65th ASH Annual Meeting and Exposition. Patients who achieved molecular residual disea…

1
Antibody-Drug Conjugate Brings Success in High-Risk R/R Follicular Lymphoma 22:11

2M ago22:11

22:11

With no standard-of-care treatment for patients with high-risk relapsed/refractory follicular lymphoma, promising remissions have been observed in a Phase II study reported at the 65th ASH Annual Meeting and Exposition. The antibody-drug conjugate loncastuximab tesirine in combination with rituximab brought a very high complete metabolic response r…

1
04_03 Metastatic Castrate Sensitive Prostate Cancer 29:02

2M ago29:02

29:02

1. The chemotherapy revolution in prostate cancer 2. Role of ARATs in earlier disease states 3. Triple therapy (chemotherapy, ADT, and ARAT) 4. Considerations for frailer patients with indolent disease Citations As always, citations, and sources include education from our respective training programs, the Devita textbook, and Uptodate.com. We highl…

1
Pirtobrutinib After Covalent BTK Inhibitor - Double Refractory CLL 12:16

3M ago12:16

12:16

Patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) have poor outcomes after the failure of covalent Bruton's tyrosine kinase (BTK) inhibitor treatment, and new therapeutic options are needed. Pirtobrutinib, a highly selective, noncovalent (reversible) BTK inhibitor, was designed to re-establish BTK inhibition.…

1
Relapsed or Refractory CLL - With Sameer A. Parikh, MBBS, and Alessandra Ferrajoli, MD 12:32

3M ago12:32

12:32

In a multinational, Phase III, head-to-head trial, ibrutinib, a Bruton's tyrosine kinase (BTK) inhibitor, was compared with zanubrutinib, a BTK inhibitor with greater specificity, as treatment for relapsed or refractory chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). In prespecified interim analyses, zanubrutinib was superio…

1
CLL Frontline Treatment - With Sameer A. Parikh, MBBS, & Alessandra Ferrajoli, MD 14:40

3M ago14:40

14:40

Randomized trials of venetoclax plus anti-CD20 antibodies as first-line treatment in fit patients (i.e., those with a low burden of coexisting conditions) with advanced chronic lymphocytic leukemia (CLL) have been lacking.

1
04_02 Adjuvant Options for Prostate Cancer 28:41

3M ago28:41

28:41

1. Physiology, efficacy and toxicities of androgen deprivation 2. Evidence for adjuvant intervention after definitive surgery or radiation 3. Role of abiraterone in high-risk localized prostate cancer 4. Limited evidence to support definitive salvage approach Citations As always, citations, and sources include education from our respective training…

1
Bouncing Back: Insights On Resilience From Your Cancer Guy 29:38

4M ago29:38

29:38

Join me, Kenny Perkins as I share insights on bouncing back from challenges, and what I have learned over the years from cancer patients. Explore resilience, overcome difficulties, and discover practical tips for navigating through tough times. I reflect on developing resilience, encouraging you to ponder your own ability to bounce back. Tune in fo…

1
04_01 Fundamentals of Localized Prostate Cancer 31:59

4M ago31:59

31:59

1. Background and presentation of prostate Cancer 2. Evidence behind PSA screening and hallmarks of a screening test 3. Staging and risk stratification of Localized Disease 4. Management options and the ProtecT Trial Citations As always, citations, and sources include education from our respective training programs, the Devita textbook, and Uptodat…

1
04_00 Introduction (Updated 12.17.23) 3:38

4M ago3:38

3:38

We have updated our initial introduction and are re-posting it here as well as in the initial file.Talking About Tumors

1
Youtube Coach Battles Cancer: Owen’s Unfiltered Story 1:12:05

5M ago1:12:05

1:12:05

In this episode, we engage in a powerful and insightful conversation with Owen, a YouTube coach and cancer survivor. Together, we explore Owen's inspiring journey on how faced cancer twice, he emphasizes the significance of a strong support system and discusses the emotional challenges he encountered. Throughout our discussion, we dive into themes …

1
Sabestomig in Non-Small Cell Lung Cancer: Bi-Specific Antibody Safe and Active 11:10

5M ago11:10

11:10

Patients with non-small cell lung cancer who have failed initial immunotherapy therapy with anti-programmed cell death ligand-1 (PDL-1) checkpoint inhibitors, have responded to a new “bispecific” antibody that targets both the programmed cell death-1 (PD-1) antibody and also the T-cell immunoglobulin and mucin domain 3 (TIM-3) molecule. Benjamin Be…

1
03_13 Head and Neck Cancer – Locally advanced and metastatic 37:18

5M ago37:18

37:18

1. Role for definitive chemotherapy and radiation 2. Controversy on induction chemotherapy 3. Considerations for nasopharyngeal cancer 4. Approach to metastatic HNSCC Citations As always, citations, and sources include education from our respective training programs, the Devita textbook, and Uptodate.com. We highly encourage review of guidelines pu…

1
Radicals Study Finds Adjuvant Radiotherapy No Benefit After Radical Prostatectomy 15:23

5M ago15:23

15:23

Patients with high-risk prostate cancer who have been treated with radical prostatectomy gain no additional advantage and face extra toxicity if they choose to have adjuvant radiotherapy. That’s according to the findings of the randomized RADICALS study, reported at the 2023 annual congress of the European Society for Medical Oncology (ESMO) held i…

1
Two Drug Combination Benefits Patients with nRAS-Mutated Melanoma Refractory to Checkpoint Inhibition 13:38

5M ago13:38

13:38

Research presented at the 2023 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics found that a combination of two drugs targeting the nRAS mutation had clinical activity in patients with checkpoint-inhibitor refractory melanoma and had potential for treating other solid tumors with mutated nRAS as their oncogenic d…

1
Collagen-Bound Interleukin 12 Converts “Cold” Tumors into “Hot” Ones 14:50

5M ago14:50

14:50

Although immunotherapies for patients with solid tumors such as melanoma can be dramatically successful, the majority of patients are resistant and require alternative treatments. While the cytokine interleukin 12 is well known for potentiating the effect of immunotherapies, such as checkpoint blockade, it could not be used because of toxicity. At …

1
Double TKI Therapy Improves Responses in MET Amplification-Driven EGFR-Mutant Non-Small Cell Lung Cancer 15:22

5M ago15:22

15:22

Among patients with non-small cell lung cancers driven by mutations in the epidermal growth factor receptor (EGFR), those with MET-amplification can now be selected for therapy with two tyrosine kinase inhibitor drugs, not just standard osimertinib. That’s according to conclusions from the INSIGHT 2 study reported at the AACR-NCI-EORTC internationa…

1
CLIC Protein Inhibition Key to Metformin’s Anti-Neoplastic Properties 24:17

5M ago24:17

24:17

The Chloride Intracellular Channel 1 (CLIC1) protein appears to hold the key to understanding the anti-proliferative action of metformin, according to laboratory evidence discussed at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics held in October 2023, in Boston. At the conference, Michele M. Mazzanti, PhD,…

1
Adjuvant ATR Inhibition Prolonged Life in Patients with Relapsed Small Cell Lung Cancer 18:59

5M ago18:59

18:59

Dr. Takahashi talks with OncTimes Talk’s Peter Goodwin about the Phase 2 study he presented at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, October 11 - 15, 2023. Dr. Takahashi reported an improvement in median overall survival among patients with relapsed small cell lung cancer who had the ATR inhibitor…

1
Mitophagy Discovered as Potential Reason for AML’s Resistance to Venetoclax 15:20

5M ago15:20

15:20

Acute myeloid leukemia (AML) is notoriously difficult to treat. Only 28 percent of patients survive beyond 5 years after diagnosis. Mitophagy, a process in which damaged mitochondria are eliminated to prevent the transmission of death signals, has been identified as a key mechanism that allows leukemia cells to resist the effects of the widely pres…

1
Empowerment Down Under: Meet Helen Beeley from Brisbane 48:15

5M ago48:15

48:15

In this episode, our guest, Helen Beeley, shares her remarkable journey, emphasizing the power of determination, a positive outlook, and the unwavering human spirit. Helen inspires us with her story. Her experiences serve as a beacon of hope, reminding us that with the right mindset, support, self-care, and resilience, we can overcome life's challe…

1
03_12 Head and Neck Cancer – Background and adjuvant considerations 23:28

6M ago23:28

23:28

1. Anatomy, diagnostic work-up and staging 2. Field cancerization 3. Indications for adjuvant concurrent chemoradiation 4. Evidence to support weekly cisplatin with concurrent radiation Citations As always, citations, and sources include education from our respective training programs, the Devita textbook, and Uptodate.com. We highly encourage revi…

1
A Tribute to a Remarkable Soul: Jessie Lee’s Cancer Journey 56:06

6M ago56:06

56:06

In this episode, we honor the memory of Jessie Lee, in her battle with colon cancer. Her inspiring journey, filled with resilience and positivity, serves as a beacon of hope. Join us as we revisit her story and celebrate her enduring spirit. This is an episode you do not want to miss. Subscribe and share with others who may find strength and inspir…

1
03_11 Mesothelioma and a bit of Large Cell Neuroendocrine Carcinoma 29:40

6M ago29:40

29:40

1. Presentation, and considerations for regional mesothelioma 2. Systemic therapy options for advanced mesothelioma 3. Corticosteroids for pemetrexed, paclitaxel and docetaxel 4. A quick review on considerations for LCNEC Citations As always, citations, and sources include education from our respective training programs, the Devita textbook, and Up…

1
A Beacon of Hope: Christine’s Inspiring Breast Cancer Survivorship 32:16

7M ago32:16

32:16

In this episode, breast cancer survivor Christine Handy shares her remarkable journey, highlighting the power of mindset, support, self-care, and resilience. Her story is a beacon of hope, reminding us that with determination and a positive outlook, we can overcome the challenges of life. Tune in for inspiration and valuable insights from Christine…

1
03_10 Small cell lung cancer 33:31

7M ago33:31

33:31

1. Background on SCLC 2. Approach to treatment by stage 3. Emerging discussion on prophylactic cranial irradiation 4. Brief review of basket and umbrella trials Citations As always, citations, and sources include education from our respective training programs, the Devita textbook, and Uptodate.com. We highly encourage review of guidelines publishe…

1
Two Battles, One Spirit: How Lauren Tarpley Conquered a Tumor and the Pandemic 40:24

8M ago40:24

40:24

Join us as we sit down with Lauren Tarpley, a resilient entrepreneur who shares her inspiring journey of overcoming a life-altering cancer diagnosis and navigating the challenges of the pandemic. Her story is one of hope, courage, and determination. For more gems and in-depth discussion, make sure to listen to the entire episode. This is an episode…

1
Unintentional Bias of Breast Cancer Randomized Clinical Trial Interpretations Through Discontinuation Imbalance 11:54

8M ago11:54

11:54

Some of the big randomized clinical trials could lead to unintentional bias because of an imbalance of assigned treatment discontinuations between experimental and control arms, according to ASCO poster author Faris Tamimi, MD, at the University Health Network Division of Medical Oncology and Hematology at Princess Margaret Cancer Centre. OncTimesT…

1
03_09 Stage III NSCLC for the Medical Oncologist 27:46

8M ago27:46

27:46

1. Refresher on T+N staging for Stage III 2. Evidence for concurrent chemoradiation 3. PACIFIC Trial 4. Encourage cessation regardless of stage of Lung Cancer Citations As always, citations, and sources include education from our respective training programs, the Devita textbook, and Uptodate.com. We highly encourage review of guidelines published …

1
Trastuzumab Deruxtecan Benefits Patients with HER2-Low Metastatic Breast Cancer Irrespective of ER Expression 11:43

8M ago11:43

11:43

Although T-DXd had already been licensed for use in all categories of HER2 positivity, including patients with so-called HER2-low tumors (defined as having immunohistochemical score of 1+ or 2+ with non-amplified in-situ hybridization), doubts have remained about the effectiveness of this antibody drug conjugate in the subset of such patients who a…

1
Artificial Intelligence Model Predicts Overall Survival in Patients with Metastatic Breast Cancer 9:17

8M ago9:17

9:17

A mathematical study of real-world data from 27,855 women whose breast cancer was diagnosed between 2008 and 2020 has shown that a machine-learning artificial intelligence algorithm was able to predict mortality and could become a key weapon in the clinician’s armory when selecting therapies on the basis of predicted survival. Initial findings and …

1
03_08 ADAURA Trial 25:58

8M ago25:58

25:58

1. Background on adjuvant EGFR therapy 2. Discussion of initial and updated results 3. Hazard Ratios and Context 4. When crossover and access limit generalizability Citations As always, citations, and sources include education from our respective training programs, the Devita textbook, and Uptodate.com. We highly encourage review of guidelines publ…

Подкасты, которые стоит послушать

Подкасты на тему Talking Oncology

Подкасты, которые стоит послушать

Краткое руководство